Worldwide Cancer Research
The arrival of COVID-19 changed the world as we knew it. Global priorities underwent seismic shifts and measures to prevent the spread of COVID-19 changed our daily and working lives beyond recognition. In this exclusive interview, we speak with Worldwide Cancer Research’s Director of Research, Dr Lynn Turner, to hear how the pandemic has impacted the ongoing battle against cancer, and what challenges must now be faced as a result.
Could you explain how individuals with cancer have been affected by the pandemic?
We know from reports, studies and analysis conducted over the past year that people with cancer have been heavily impacted by the pandemic. We are concerned that people with cancer are in danger of becoming collateral damage as a result of everyone’s attention being focussed on ‘the other C’ – COVID-19. Across the UK, the pandemic has led to delays in diagnosis and treatment, which researchers estimate could lead to anywhere between 7,000 and 18,000 additional deaths from cancer in 2021. We also saw early in the nationwide lockdown that there was a significant decline in the number of people being referred to emergency cancer services. This is truly worrying and it’s vitally important that people remember to still see their GP if they suspect any sign or symptom of cancer so that they can be referred to a specialist if needed.
How has your work, and research into cancer more generally, been affected by the COVID-19 pandemic?
When the pandemic hit in 2020, we saw a rapid shut down across the world of nearly all our research projects due to university and research institute closures. There were some exceptions, such as in Israel, where our scientists were still able to go to the lab to conduct their research. But even then, they were working at a reduced capacity, with strict social distancing and safety measures in place to protect people.
One thing we felt was important was to make sure that our researchers did not feel pressured in the face of delays caused by lab closures. We offered all our researchers the chance to extend the length of their projects to make up for the lost time. We also allowed the researchers who were just about to start their projects, when the pandemic hit, to delay their start date.
We also had to react quickly internally to shift our annual Big Ideas Gathering, where our Scientific Advisory Committee makes the final decision on which new projects to fund, from a face-to-face meeting to a virtual one. This came with its own set of challenges, but the team did a fantastic job adjusting and we were delighted to be able to make a commitment to fund 16 new projects which will start in 2021.
Can you speculate as to the longer-term consequences of the pandemic for cancer research?
This is a difficult question to speculate an answer to, but we do know that charity-funded medical research is under threat all over the world. In the UK, the sector invested an estimated £1.9 billion in medical research in 2019, which is around half of all publicly funded medical research. The sector is now facing a 40% decrease in medical research spend over the next year and a shortfall of £310 million caused by the impact on fundraising. It’s expected that it will take four and a half years for the sector to recover – something that could have a devastating impact on people diagnosed with cancer in the future.
Despite the significant and unprecedented challenges, what positives have arisen for cancer research over the last year?
COVID-19 undoubtedly slowed scientific research all over the world in 2020, but science has not stopped completely. Scientists supported by Worldwide Cancer Research have contributed to several important breakthroughs in 2020 – including a new cancer vaccine that could enter clinical trials within the next three years and a game-changing treatment for prostate cancer that could be available to patients within four years.
We were also delighted that, thanks to the generosity of our supporters, we were still able to fund new projects this year. We invested over £3.2million in 16 new projects happening in 11 countries around the world. Knowing that we will continue to start new cancer cures gives us, our supporters and people affected by cancer, much-needed hope for the future.
‘…people with cancer are in danger of becoming collateral damage as a result of everyone’s attention being focussed on “the other C” – COVID-19.’
Finally, how can we ensure that cancer research remains a priority in such challenging times?
The type of research Worldwide Cancer Research funds is what we call discovery research. It’s the starting point from which new ways to prevent, diagnose and treat cancer emerge. Without it, we would not have the foundations to build on and we could miss out on future lifesaving discoveries. We must continue to fund this type of research to keep the ideas flowing down the pipeline – now is the time to invest in our future. As we have seen with the amazing response to COVID-19, research is essential to progress. And putting money behind research and those that fund it means that we can make progress faster.
People have woken up to the power of science and research to solve global problems. With 1 in 2 of us in the UK predicted to receive a cancer diagnosis during our lifetime, this is the time to use the momentum we have gained and use it to tackle the ‘big C’.
Reference
https://doi.org/10.33548/SCIENTIA651
Want to republish our articles?
We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more
Creative Commons Licence
(CC BY 4.0)
This work is licensed under a Creative Commons Attribution 4.0 International License. 
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
More articles you may like
Dr JoLee Sasakamoose – Dr Mamata Pandey | Empowering Indigenous Health: The Indigenous Wellness Research Collaborative in Saskatchewan
The Indigenous Wellness Research Collaborative is a transformative alliance dedicated to advancing health systems and service delivery for Indigenous communities across Saskatchewan. Founded a decade ago and co-led by Dr Mamata Pandey, a research scientist at the Saskatchewan Health Authority, and Dr JoLee Sasakamoose (M’Chigeeng First Nation), Canadian Institute of Health Research Chair in Indigenous Wellness and Health Equity at the University of Regina, their team’s work is rooted in a commitment to Indigenous leadership and community-defined wellness goals. Guided by the Cultural Responsiveness Framework, the Collaborative prioritises creating ethical spaces that serve as a middle ground for respect, reciprocity, and authentic partnerships. The team employs a strengths-based approach to health research, centering Indigenous methodologies that respect the interconnectedness of spiritual, mental, emotional, and physical well-being.
Dr Amy B. Zelenski | Can Digital Tools Effectively Teach Medical Students Clinical Skills?
Medical students often experience a decline in empathy as they progress through their training, an issue with real consequences for patient care. A new study from the University of Wisconsin explores an unexpected remedy: Zoom-based improvisational theatre. In the first randomized controlled trial of its kind, researchers found that short online improv sessions helped students improve perspective-taking, reduce emotional distress, and deeply reflect on patient relationships and power dynamics. As telemedicine becomes increasingly common, this approach to teaching empathy could offer a timely, effective, and engaging tool to help future doctors more meaningfully connect with their patients.
Professor Jaya Krishnan | Revolutionary Gene Therapy Helps Hearts Regenerate After Heart Attacks
Myocardial infarction, commonly termed as a heart attack, is a major cause of death and poor health worldwide. Regenerating heart tissue is an exciting and promising concept that can have significant benefits in myocardial infarctions and related diseases, but this has not yet been achieved in real-life clinical treatments. In a collaboration between Goethe University Frankfurt and Goethe University Hospital, Professor Jaya Krishnan and colleagues address this by controlling pathologic genes involved in the development of heart failure that develops after heart attacks. The researchers demonstrate a new way of treating heart disease by aiding in the division and regrowth of heart cells after a heart attack.
Dr Yaakov Glick | Brightness Enhancement with Raman Fibre Lasers
Both Raman fibre lasers (lasers based on stimulating molecules to emit photons at a given frequency shift from the pump laser) and Rare Earth fibre lasers (which use rare earth elements to emit light) work as fibre-based laser sources. Scientists have become interested in Raman fibre lasers because Rare Earth lasers have power limitations, due to the excess heat generated by the lasing process. Dr Yaakov Glick and his colleagues in the Applied Physics Division, at Soreq Nuclear Research Centre in Yavne, Israel, collaborating internationally with other groups, have worked to increase the power of Raman fibre lasers, while simultaneously enhancing their brightness.